Search

CN-122005603-A - Combination of ergothioneine and achyranthes polysaccharide for inhibiting HPV and preparation method thereof

CN122005603ACN 122005603 ACN122005603 ACN 122005603ACN-122005603-A

Abstract

The invention discloses an ergothioneine and achyranthes polysaccharide composition for inhibiting HPV and a preparation method thereof, and relates to the technical field of biological medicine. The composition comprises, by mass, 1-5 parts of ergothioneine, 3-10 parts of achyranthes polysaccharide, 0.2-1.2 parts of CXCR4 antagonist, 0.5-2 parts of sodium hyaluronate, 10-20 parts of polyalcohol cosolvent and 60-80 parts of deionized water, wherein the CXCR4 antagonist has a specific structure of formula 1. The composition realizes multi-mechanism synergistic effect through targeted intervention of CXCR4 antagonist, stable synergy of achyranthes polysaccharide delivery network construction and ergothioneine, and is beneficial to improving the inhibition effect on HPV infection and the preparation stability.

Inventors

  • ZHANG WEI
  • WU MENGYAO

Assignees

  • 上海麦角硫因生物科技集团有限公司

Dates

Publication Date
20260512
Application Date
20260112

Claims (10)

  1. 1. A combination of ergothioneine and achyranthes polysaccharide for inhibiting HPV, comprising a CXCR4 antagonist of formula 1; The structure of formula 1 is: Formula 1; r 1 in the formula 1 is a substituent; And R 1 is selected from any one of methyl, ethyl, propyl, methoxy, ethoxy, benzyloxy and piperidyl.
  2. 2. The combination of ergothioneine and achyranthes polysaccharide for inhibiting HPV according to claim 1, wherein R 1 is selected from any one of methyl, methoxy, benzyloxy, piperidinyl.
  3. 3. The combination of ergothioneine and achyranthes polysaccharide inhibiting HPV of claim 1, wherein the CXCR4 antagonist is one of the compounds of the following structure: ; 。
  4. 4. The combination of ergothioneine and achyranthes polysaccharide for inhibiting HPV according to claim 1, wherein the combination consists of 1-5 parts by mass of ergothioneine, 3-10 parts by mass of achyranthes polysaccharide, 0.2-1.2 parts by mass of CXCR4 antagonist, 0.5-2 parts by mass of sodium hyaluronate, 10-20 parts by mass of polyalcohol cosolvent and 60-80 parts by mass of deionized water.
  5. 5. A combination of ergothioneine and achyranthes polysaccharide inhibiting HPV according to claim 4, wherein the polyhydric alcohol co-solvent is selected from one or more of propylene glycol, glycerol, 1, 3-butanediol.
  6. 6. The combination of ergothioneine and achyranthes polysaccharide inhibiting HPV according to claim 4, wherein the average molecular weight of achyranthes polysaccharide is 1000-5000Da.
  7. 7. A composition of ergothioneine and achyranthes polysaccharide inhibiting HPV according to claim 4, the method is characterized in that the mass purity of the ergothioneine is more than or equal to 99%.
  8. 8. A method of preparing an HPV-inhibiting ergothioneine and achyranthes polysaccharide composition according to any one of claims 4-7, comprising the steps of: a. adding achyranthes bidentata polysaccharide and sodium hyaluronate into deionized water, stirring and dissolving at 40-50 ℃ to form a water phase matrix; b. adding the CXCR4 antagonist into a polyalcohol cosolvent, and carrying out ultrasonic treatment at 55-65 ℃ until the CXCR4 antagonist is completely dissolved to obtain an active substance premix; c. adding the ergothioneine into the aqueous phase matrix, and stirring in a dark place until the ergothioneine is completely dissolved; d. Under the condition of high-speed shearing, slowly dripping the active substance premix into an aqueous phase matrix containing ergothioneine, controlling the shearing rate to be 5000-8000rpm, and enabling the CXCR4 antagonist to perform supermolecule self-assembly in a molecular network formed by achyranthes bidentata polysaccharide to obtain a micro-nano level dispersion system.
  9. 9. The method for preparing a composition of ergothioneine and achyranthes polysaccharide for inhibiting HPV according to claim 8, wherein the power of the ultrasonic treatment in the step b is 200-400W and the treatment time is 15-30min.
  10. 10. The method for preparing a composition of ergothioneine and achyranthes polysaccharide for inhibiting HPV according to claim 8, wherein after the completion of the dripping in the step d, the vacuum defoaming treatment is continuously carried out under the condition of 30-35 ℃ and the pH value of the system is adjusted to 5.5-6.5.

Description

Combination of ergothioneine and achyranthes polysaccharide for inhibiting HPV and preparation method thereof Technical Field The invention relates to the technical field of biological medicine, in particular to an ergothioneine and achyranthes polysaccharide composition for inhibiting HPV and a preparation method thereof. Background Currently, intervention means against Human Papillomavirus (HPV) infection, especially topical formulations, are mostly focused on acting through immunomodulation or direct disruption of the viral envelope. For example, some plant polysaccharide or antioxidant-based compositions, which are used to indirectly inhibit viruses mainly by enhancing local immunity or scavenging free radicals, have a relatively single target site of action, have limited efficacy on HPV viruses that have entered cells and established latent infection, and are difficult to fundamentally block the critical pathways for replication of the virus using host cell mechanisms. This results in significant deficiencies of existing products in terms of thoroughness in viral clearance and prevention of recurrence. In terms of ingredient constitution, many prior art techniques simply physically mix the various active ingredients, lacking a synergistic effect between the components. For example, certain compositions, while containing substances with good biological activity such as ergothioneine, have poor transdermal absorption and stability and fail to form an effective delivery system with other components (e.g., macromolecular polysaccharides), which can lead to a significant loss of bioavailability and limit the full use of their efficacy. In addition, the overall inhibition efficiency of the composition is faced with a bottleneck if it focuses only on inhibition of a single link, but fails to effectively interfere with multiple key nodes in the viral life cycle, such as viral adsorption, penetration, etc. From the point of view of formulation technology, it is a challenge to effectively integrate active ingredients with different physicochemical properties, in particular hydrophobic small molecule drugs, with hydrophilic macromolecular polysaccharides. The conventional mixing and stirring method is difficult to ensure uniform dispersion and long-term stability of the hydrophobic active ingredients in the hydrophilic matrix, and is easy to cause precipitation, aggregation and other problems, and the uniformity, stability and final use effect of the product are directly affected. Therefore, the development of a composition which can realize efficient synergy of all components, has good physical stability and can play a role in a plurality of links of HPV infection has important significance. Disclosure of Invention Aiming at the problems of single HPV inhibition target point, insufficient synergistic effect among active ingredients, poor physical stability of the preparation, uneven dispersion of hydrophobic ingredients and the like in the prior art, the invention provides the composition of the ergothioneine and the achyranthes bidentata polysaccharide for inhibiting HPV, which has definite multi-mechanism synergistic effect, good compatibility among components, high stability, high-efficiency virus inhibition and skin barrier repair realization and stable HPV infection intervention. To achieve an anti-aging effect, an spermidine composition comprises a CXCR4 antagonist represented by the structure of formula 1: Formula 1; r 1 in the formula 1 is a substituent; And R 1 is selected from any one of methyl, ethyl, propyl, methoxy, ethoxy, benzyloxy and piperidyl. Further, the R 1 is selected from any one of methyl, methoxy, benzyloxy and piperidinyl. Further, the CXCR4 antagonist is one of the compounds shown in the following structures: ; 。 A combination of ergothioneine and achyranthes polysaccharide for inhibiting HPV comprises, by mass, 1-5 parts of ergothioneine, 3-10 parts of achyranthes polysaccharide, 0.2-1.2 parts of CXCR4 antagonist, 0.5-2 parts of sodium hyaluronate, 10-20 parts of polyalcohol cosolvent and 60-80 parts of deionized water. Further, the polyol cosolvent is selected from one or more of propylene glycol, glycerol and 1, 3-butanediol. Further, the achyranthes bidentata polysaccharide is an acidic polysaccharide with the average molecular weight of 1000-5000Da, which is prepared by a water extraction and alcohol precipitation process. Further, the mass purity of the ergothioneine is more than or equal to 99%. A method for preparing an HPV-inhibiting ergothioneine and achyranthes polysaccharide composition, comprising the steps of: a. adding achyranthes bidentata polysaccharide and sodium hyaluronate into deionized water, stirring and dissolving at 40-50 ℃ to form a water phase matrix; b. adding the CXCR4 antagonist into a polyalcohol cosolvent, and carrying out ultrasonic treatment at 55-65 ℃ until the CXCR4 antagonist is completely dissolved to obtain an active substance premix; c. adding th